Recurrent granulomatous panniculitis in a patient with autoimmune disease: Bazin's indurated erythema or immune-mediated manifestation?
DOI:
https://doi.org/10.32818/reccmi.a10n3a14Keywords:
erythema induratum of Bazin, panniculitis, autoimmunity, cutaneous tuberculosis, immunosuppressantsAbstract
A young woman with a history of untreated rheumatoid arthritis and Sjögren's syndrome was diagnosed with Bazin's erythema induratum of active tuberculous etiology. After a good initial response to antifimic therapy, she relapsed upon entering the maintenance phase, which led to suspicion of resistance to isoniazid or rifampin. She was then transferred to a nine-month treatment with all four drugs, with complete resolution of the lesions. A few months later, she experienced a second relapse, this time immune-mediated in the absence of bacilli. The patient showed an excellent clinical response following immunosuppressants, confirming the autoimmune origin of the process at the second stage.
Downloads
Metrics
References
Bravo FG, Gotuzzo E. Cutaneous tuberculosis. Clin Dermatol. 2007; 25(2): 173-80. doi: https://doi.org/10.1016/j.clindermatol.2006.05.005 (último acceso dic. 2025). DOI: https://doi.org/10.1016/j.clindermatol.2006.05.005
Yang K, Li T, Zhu X, Zou Y, Liu D. Erythema induratum of Bazin as an indicative manifestation of cavitary tuberculosis in an adolescent: a case report. BMC Infect Dis. 2021; 21(1): 747. doi: https://doi.org/10.1186/s12879-021-06454-4 (último acceso dic. 2025). DOI: https://doi.org/10.1186/s12879-021-06454-4
World Health Organization. WHO operational handbook on tuberculosis. Module 4: treatment–drug-resistant tuberculosis treatment. Geneva: World Health Organization; 2022. Disponible en: https://www.who.int/publications/i/item/9789240065116 (último acceso dic. 2025).
Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, et al. Executive summary: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America (ATS/CDC/IDSA) clinical practice guidelines: treatment of drug-susceptible tuberculosis. Clin Infect Dis. 2016; 63(7): 853-67. doi: https://doi.org/10.1093/cid/ciw566 (último acceso dic. 2025). DOI: https://doi.org/10.1093/cid/ciw566
Samayoa-Peláez M, Ayala N, Yadon ZE, Heldal E. Implementation of the national tuberculosis guidelines on culture and drug sensitivity testing in Guatemala. 2013. Rev Panam Salud Publica. 2016; 39(1): 44–50. Accesible en: https://iris.paho.org/handle/10665.2/28201 (último acceso dic. 2025).
Balogh EA. Eritema indurado (vasculitis nodular) Presentación clínica. 2024. Accesible en: https://emedicine.medscape.com/article/1083213-clinical (último acceso dic. 2025).
Segura S, Pujol RM, Trindade F, Requena L. Vasculitis in erythema induratum of Bazin: a histopathologic study of 101 biopsy specimens from 86 patients. J Am Acad Dermatol. 2008; 59(5): 839-51. doi: https://doi.org/10.1016/j.jaad.2008.07.030 (último acceso dic. 2025). DOI: https://doi.org/10.1016/j.jaad.2008.07.030
Mofarrah R, Jallab N, Mofarrah R, Jahani Amiri K, Jallab N. Nodular vasculitis or erythema induratum without cutaneous tuberculosis: an unusual presentation in an uncommon site. Our Dermatol Online. 2021; 12(2): 174–76. doi: https://doi.org/10.7241/ourd.2021.2.8 (último acceso dic. 2025). DOI: https://doi.org/10.7241/ourd.20212.8
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Luis Alejandro López-Yepes, Ana Lucía Urrutia-Brán
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Permite compartir, copiar y redistribuir el material en cualquier medio o formato, bajo los siguientes términos:
Reconocimiento: debe otorgar el crédito correspondiente, proporcionar un enlace a la licencia e indicar si se realizaron cambios. Puede hacerlo de cualquier manera razonable, pero no de ninguna manera que sugiera que el licenciante lo respalda a usted o su uso.
No comercial: no puede utilizar el material con fines comerciales.
No Derivados: si remezcla, transforma o construye sobre el material, no puede distribuir el material modificado.
Sin restricciones adicionales: no puede aplicar términos legales o medidas tecnológicas que restrinjan legalmente a otros de hacer cualquier cosa que permita la licencia.
